2021
Extent of High-Grade Prostatic Adenocarcinoma in Multiparametric Magnetic Resonance Imaging-Targeted Biopsy Enhances Prediction of Pathologic Stage.
Paulson N, Vollmer RT, Humphrey PA, Sprenkle PC, Onofrey J, Huber S, Amirkhiz K, Levi AW. Extent of High-Grade Prostatic Adenocarcinoma in Multiparametric Magnetic Resonance Imaging-Targeted Biopsy Enhances Prediction of Pathologic Stage. Archives Of Pathology & Laboratory Medicine 2021, 146: 201-204. PMID: 34015819, DOI: 10.5858/arpa.2020-0568-oa.Peer-Reviewed Original ResearchConceptsMpMRI-targeted biopsiesHigh-grade prostatic adenocarcinomaMultiparametric magnetic resonance imagingHG PCaRadical prostatectomyHigh-grade groupMagnetic resonance imagingPathologic stageRP outcomesProstatic adenocarcinomaGrade Group 2 diseaseResonance imagingGrade groupProstate-confined diseaseSeminal vesicle involvementLymph node metastasisHigher pathologic stageAdditional predictive valueLogistic regression modelsLinear millimeterNode metastasisRetrospective reviewAdverse outcomesTargeted biopsiesProstate biopsy
2020
Magnetic Resonance Imaging-Guided Transurethral Ultrasound Ablation of Prostate Cancer.
Klotz L, Pavlovich CP, Chin J, Hatiboglu G, Koch M, Penson D, Raman S, Oto A, Fütterer J, Serrallach M, Relle J, Lotan Y, Heidenreich A, Bonekamp D, Haider M, Tirkes T, Arora S, Macura KJ, Costa DN, Persigehl T, Pantuck AJ, Bomers J, Burtnyk M, Staruch R, Eggener S. Magnetic Resonance Imaging-Guided Transurethral Ultrasound Ablation of Prostate Cancer. Journal Of Urology 2020, 205: 769-779. PMID: 33021440, DOI: 10.1097/ju.0000000000001362.Peer-Reviewed Original ResearchConceptsGrade Group 2 diseaseProstate-specific antigen reductionGrade group 2Whole gland ablationTransurethral ultrasound ablationAntigen reductionMagnetic resonance imagingProstate cancerGroup 2Gland ablationMagnetic resonance imaging-guided transurethral ultrasound ablationGrade 3 adverse eventsResonance imagingTarget volumeEvidence of cancerUltrasound ablationIntermediate-risk diseaseRisk prostate cancerProspective multicenter trialMedian prostate volumeLocalized prostate cancerMedian treatment delivery timeTreatment delivery timeMagnetic resonancePrimary endpoint
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply